| Description | Deutetrabenazine metabolite M4 is believed to be related to its effect as a reversible depletion of monoamines from nerve terminals. The major circulating metabolites of Deutetrabenazine, are reversible inhibitors of VMAT2, resulting in decreased uptake of monoamines into synaptic vesicles and depletion of monoamine stores. |
| Synonyms | SD-1018, Deuterated monohydroxy tetrabenazine, D6-tetrabenazine metabolite M4 |
| molecular weight | 339.46 |
| Molecular formula | C19H21D6NO4 |
| CAS | 1688661-95-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Huntington Study Group, Frank S, Testa CM,et al. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA. 2016 Jul 5;316(1):40-50. doi: 10.1001/jama.2016.8655. PubMed PMID: 27380342. 2. Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy T, Shprecher D, Stamler D. Deutetrabenazine in Tics Associated with Tourette Syndrome. Tremor Other Hyperkinet Mov (N Y). 2016 Nov 7;6:422. eCollection 2016. PubMed PMID: 27917309; PubMed Central PMCID: PMC5133390. 3. Geschwind MD, Paras N. Deutetrabenazine for Treatment of Chorea in Huntington Disease. JAMA. 2016 Jul 5;316(1):33-5. doi: 10.1001/jama.2016.8011. PubMed PMID: 27380339. 4. Reilmann R. Deutetrabenazine-Not a Revolution but Welcome Evolution for Treating Chorea in Huntington Disease. JAMA Neurol. 2016 Dec 1;73(12):1404-1406. doi: 10.1001/jamaneurol.2016.3916. PubMed PMID: 27749952. |
Deutetrabenazine metabolite M4
CAS No.: 1688661-95-1
Deutetrabenazine metabolite M4is believed to be related to its effect as a reversible depletion of monoamines from nerve
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.